The Centers for Medicare and Medicaid Services’ recently-proposed national coverage determination restricting reimbursement for amyloid-directed monoclonal antibody drugs for Alzheimer’s disease to use in clinical trials undermines the commercial value of an accelerated approval in the class, according to Eli Lilly and Company.
Lilly no longer believes an accelerated approval from the US Food and Drug Administration for its Alzheimer’s drug candidate donanemab...







